Immunotherapy in liver tumors: II. Intratumoral injection with activated tumor-infiltrating lymphocytes, intrasplenic administration of recombinant interleukin-2 and interferon alpha causes tumor regression and lysis
- PMID: 7923100
- DOI: 10.1016/0304-3835(94)90236-4
Immunotherapy in liver tumors: II. Intratumoral injection with activated tumor-infiltrating lymphocytes, intrasplenic administration of recombinant interleukin-2 and interferon alpha causes tumor regression and lysis
Abstract
This study tested the effect of intratumoral injection with activated tumor-infiltrating lymphocytes (TIL), and simultaneous administration of recombinant interleukin-2 (rIL-2) and interferon alpha (IFN-alpha) (LII protocol), on mouse liver tumor. Group I (n = 10) served as the controls. Group II (n = 17) received rIL-2 + IFN-alpha schedule. Group III (n = 20) received the LII protocol. A total of 5 x 10(6) of TIL were injected into 4 sites of a tumor in a single treatment. rIL-2 (1 x 10(6) IU) on the first day and IFN-alpha (1 x 10(5) IU) on the second day were alternately given with a total of 10 treatment doses that were completed in 20 days. Tumor remission or regression rates of 29% and 40% were obtained in groups II and III, respectively, but no remission was obtained in the controls. A large number of TIL were also observed in the tumors treated with the LII protocol. Making comparisons between the control group and IL-2 + IFN-alpha schedule, and the control group and LII protocol, the ratios of cytolytic activity of TIL in vitro were 0:32 and 0:57, respectively. We conclude that the LII protocol appears to be more effective in the treatment of mouse liver tumor than the IL-2 + IFN-alpha schedule, and that it may be a new promise for the treatment of patients with liver malignancies.
Similar articles
-
Immunotherapy in liver tumors: III. A new experimental model of metastatic liver tumors from colorectal carcinoma for cytokine therapy.Cancer Lett. 1995 Jan 27;88(2):211-19. doi: 10.1016/0304-3835(94)03623-q. Cancer Lett. 1995. PMID: 7874695
-
Immunotherapy in liver tumours: I. Combined administration of recombinant interleukin-2 (IL-2) and interferon-alpha through the subcutaneous transposed spleen prolongs the half-life of IL-2 in vivo and enhances antitumor effects.Cancer Lett. 1994 Sep 30;85(1):31-7. doi: 10.1016/0304-3835(94)90235-6. Cancer Lett. 1994. PMID: 7923099
-
Chemo-adoptive immunotherapy of nude mice implanted with human colorectal carcinoma and melanoma cell lines.Cancer Immunol Immunother. 1992;35(2):135-44. doi: 10.1007/BF01741861. Cancer Immunol Immunother. 1992. PMID: 1596937 Free PMC article.
-
Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study.J Clin Oncol. 1995 Aug;13(8):1939-49. doi: 10.1200/JCO.1995.13.8.1939. J Clin Oncol. 1995. PMID: 7636534 Clinical Trial.
-
Recombinant interleukin-2-based treatments for advanced melanoma: the experience of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group.Cancer J Sci Am. 1997 Dec;3 Suppl 1:S22-8. Cancer J Sci Am. 1997. PMID: 9457389 Review.
Cited by
-
Trial Watch: Adoptive cell transfer for anticancer immunotherapy.Oncoimmunology. 2013 May 1;2(5):e24238. doi: 10.4161/onci.24238. Oncoimmunology. 2013. PMID: 23762803 Free PMC article.
-
Trial Watch: Adoptive cell transfer for oncological indications.Oncoimmunology. 2015 May 5;4(11):e1046673. doi: 10.1080/2162402X.2015.1046673. eCollection 2015 Nov. Oncoimmunology. 2015. PMID: 26451319 Free PMC article. Review.
-
Trial Watch: Adoptive cell transfer immunotherapy.Oncoimmunology. 2012 May 1;1(3):306-315. doi: 10.4161/onci.19549. Oncoimmunology. 2012. PMID: 22737606 Free PMC article.
-
Trial Watch: Adoptively transferred cells for anticancer immunotherapy.Oncoimmunology. 2017 Aug 11;6(11):e1363139. doi: 10.1080/2162402X.2017.1363139. eCollection 2017. Oncoimmunology. 2017. PMID: 29147628 Free PMC article. Review.
-
Immunotherapeutic Agents for Intratumoral Immunotherapy.Vaccines (Basel). 2023 Nov 14;11(11):1717. doi: 10.3390/vaccines11111717. Vaccines (Basel). 2023. PMID: 38006049 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources